secwatch.observer — SEC 8-K summary
======================================

Issuer:     XBiotech Inc. (XBIT)
CIK:        0001626878
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001171843-25-004066
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

XBiotech appoints Dr. Thomas Kündig and Craig Rademaker to Board of Directors
-----------------------------------------------------------------------------

- Dr. Thomas Kündig, Director of Dermatology at University Hospital Zurich, appointed to Board and Compensation Committee effective June 24, 2025.
- Craig Rademaker, private equity leader with 25+ years in finance, appointed to Board and Audit Committee, effective same date.
- Both appointments expire at the 2025 Annual General Meeting; committees now include Jan-Paul Waldin, Dr. Peter Libby, and the new members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626878/000117184325004066/0001171843-25-004066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626878/000117184325004066/f8k_062425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer